Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | +3.91% | +5.29% | +35.03% |
Sales 2024 * | 9.22M 768M | Sales 2025 * | 5.09M 424M | Capitalization | 447M 37.27B |
---|---|---|---|---|---|
Net income 2024 * | -77M -6.42B | Net income 2025 * | -92M -7.67B | EV / Sales 2024 * | 37.4 x |
Net cash position 2024 * | 102M 8.53B | Net cash position 2025 * | 144M 11.99B | EV / Sales 2025 * | 59.6 x |
P/E ratio 2024 * |
-5.89
x | P/E ratio 2025 * |
-5.03
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.23% |
Latest transcript on Taysha Gene Therapies, Inc.
1 day | +3.91% | ||
1 week | +5.29% | ||
Current month | -16.72% | ||
1 month | -24.61% | ||
3 months | +61.49% | ||
6 months | +7.90% | ||
Current year | +35.03% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Nolan
CEO | Chief Executive Officer | 56 | 01/20/01 |
Kamran Alam
DFI | Director of Finance/CFO | 46 | 01/20/01 |
President | 58 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Donenberg
BRD | Director/Board Member | 63 | 31/20/31 |
Sean Nolan
CEO | Chief Executive Officer | 56 | 01/20/01 |
Sean Stalfort
BRD | Director/Board Member | 54 | 21/23/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.39 | +3.91% | 890,189 |
25/24/25 | 2.3 | -2.13% | 1,560,849 |
24/24/24 | 2.35 | -7.11% | 794,093 |
23/24/23 | 2.53 | +2.85% | 1,459,037 |
22/24/22 | 2.46 | +8.37% | 1,459,716 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.03% | 447M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TSHA Stock